Our investigational quadrivalent influenza virus subunit vaccine (adjuvanted) adopts the marketed MF59-like adjuvant, an oil-in-water adjuvant mainly composed of squalene. After injection, it can activate bone marrow-derived cells such as macrophages and dendritic cells. These activated cells produce chemokines, which recruit various immune cells to the injection site, amplify the immune response, and help activate B cells and T cells in lymph nodes, thereby enhancing the intensity and duration of the immune response.Our investigational vaccine is made from influenza A and B virus strains recommended by the World Health Organization (WHO). These virus strains are cultured in chicken embryos, then undergo a series of purification processes similar to those of the quadrivalent influenza virus subunit vaccine, and finally mixed with the MF59-like adjuvant to form a multi-strain formulation. Our investigational quadrivalent influenza virus subunit vaccine (adjuvanted) obtained Investigational New Drug (IND) approval in July 2024, and it is expected to initiate Phase I clinical trials in the fourth quarter of 2025.

For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.